ASBP Key Statistics, Chart & Performance
The current stock price of ASBP is 0.092 USD. In the past month the price decreased by -73.57%.
ASBP Latest News, Press Relases and Analysis
ASBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.13 | 959.08B | ||
| JNJ | JOHNSON & JOHNSON | 19.51 | 487.84B | ||
| MRK | MERCK & CO. INC. | 11.45 | 250.41B | ||
| PFE | PFIZER INC | 8.03 | 146.12B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.92 | 105.76B | ||
| ZTS | ZOETIS INC | 18.99 | 53.06B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.60B | ||
| VTRS | VIATRIS INC | 4.62 | 12.39B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.93B | ||
| CORT | CORCEPT THERAPEUTICS INC | 96.2 | 8.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.28B |
Related stock screener links
About ASBP
Company Profile
Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Company Info
ASPIRE BIOPHARMA HOLDINGS IN
194 Candelaro Drive, #233
Humacao NEW YORK PR
Employees: 0
Phone: 15617048527
ASPIRE BIOPHARMA HOLDINGS IN / ASBP FAQ
What does ASBP do?
Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
What is the stock price of ASPIRE BIOPHARMA HOLDINGS IN today?
The current stock price of ASBP is 0.092 USD. The price increased by 3.25% in the last trading session.
Does ASBP stock pay dividends?
ASBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ASBP stock?
ASBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is ASPIRE BIOPHARMA HOLDINGS IN (ASBP) stock traded?
ASBP stock is listed on the Nasdaq exchange.
Can you provide the short interest for ASBP stock?
The outstanding short interest for ASPIRE BIOPHARMA HOLDINGS IN (ASBP) is 5.52% of its float.
ASBP Technical Analysis
ASBP Financial Highlights
Over the last trailing twelve months ASBP reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -352.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2768.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |